EGFR mutation plasma screening
Are you a medical professional?

What is EGFR?

Epidermal growth factor receptor (EGFR) is a protein found on the surface of cells. It helps cells grow and divide. It is usually the primary target in targeted therapies.

How does EGFR mutation cause lung cancer?

Some non-small cell lung cancer (NSCLC) cells have too many EGFR proteins, which cause them to grow faster. Mutations in the EGFR are present in 10 percent to about 25 percent of NSCLC tumors.

High quality EGFR mutations screening with a simple blood draw

Pangenia EGFR Mutation Plasma Screening detects EGFR gene mutations in circulating cell free tumor DNA (cfDNA) found in NSCLC patients.

Instead of taking sample directly from the tumor site, Pangenia EGFR mutation plasma screening can capture DNA shed by tumors or cancer cells in the blood. This noninvasive procedure completely simplifies the sample taking process. Pangenia EGFR mutation plasma screening can eliminate the discomfort caused to patients and valuable time used for waiting. This is exceptionally beneficial for patients who have difficulties performing bronchoscopy or other form of biopsies.

Who should consider this test?

Diagnosed/ Suspected lung cancer patients. Pangenia EGFR mutation plasma screening also facilitates the sampling of patients who are not able to sample by bronchoscopy or other form of biopsy, e.g. elderlies.

Test Specifications

Test Code
Methodology
Specimen Requirements
Turnaround Time
OPE
Real-time PCR (RT-PCR)
6 mL blood in EDTA tube
3 days

What should I do if my test results are positive?

Please consult your physicians for professional advices.

How to get started

Our tests must be ordered by a doctor. Ask your doctor if a Mygenia test is right for you. We can help you find a doctor if you don’t have one.

I have a doctor
References
  1. Lynch, Thomas J., et al. "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib."New England Journal of Medicine 350.21 (2004): 2129-2139
  2. Paez, J. Guillermo, et al. "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy." Science 304.5676 (2004): 1497-1500
  3. Pao, William, and Nicolas Girard. "New driver mutations in non-small-cell lung cancer." The lancet oncology 12.2 (2011): 175-180
  4. http://www.medicaldaily.com/liquid-biopsies-and-blood-tests-can-detect-cancer-may-revolutionize-cancer-treatment-332796
  5. http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-treating-targeted-therapies